Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
about
The PCSK9 decadeHepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberineHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesA PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivoIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorLarge scale association analysis identifies three susceptibility loci for coronary artery diseaseMutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein StructureA proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolThe proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathwayMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.Chronic social defeat stress disrupts regulation of lipid synthesisStrong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamstersJanus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cellsA two-step binding model of PCSK9 interaction with the low density lipoprotein receptorEffects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.Role of an intramolecular contact on lipoprotein uptake by the LDL receptorTargeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.PCSK9 is a critical regulator of the innate immune response and septic shock outcome.Akt inhibition promotes ABCA1-mediated cholesterol efflux to ApoA-I through suppressing mTORC1.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamstersLow prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cellsDyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed ratsStrategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.PCSK9 Inhibitors: potential in cardiovascular therapeutics.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.
P2860
Q24615397-4ECA85D1-90C2-4488-865D-3D7B8CB69E45Q24652495-88511624-AB80-4B3E-87C5-09C67ADB38D1Q26786549-F616F514-A66B-4FCC-A881-57E834480EEFQ27009477-1D7532D2-BEC9-4CAD-9D5B-26D2E67C76D9Q27013494-B3359F70-A0D2-4178-8B29-FD990908C107Q27339783-71055FBF-ACE0-4F7E-9BCE-1E494D3E8D6BQ27655476-DFCD2CA1-E3BF-4D4E-BDEF-FE7A7108C119Q27665195-30DAD266-A12A-4A96-AFAA-2421C994F8AFQ27680601-566DB005-668D-4B90-8A93-A5EC5A19EC9DQ28740844-032657F4-27C9-471B-A9C8-74C8873870DEQ30426857-E5B19800-DB52-42B3-93C6-B28D98CB8450Q33532964-BA75625C-F245-4D73-BB52-3364C63AE2D2Q33577851-F57E5162-093E-4B52-B27A-9310ABE3B731Q33599961-A564EFA2-8F90-48DE-9C01-048C86433D36Q34053143-86F4C81D-D351-4D42-8710-EE27FC4276ABQ34355679-868730B1-8A12-4953-ACE0-8C7915957306Q34455663-C7578230-F889-411D-A6A2-6AE28BA08B3AQ34458693-E91A8022-C23A-4064-A487-AA9F8AFB8E63Q34479132-1B4E0564-D2E4-4C61-ADAF-859BEFB227F7Q34559843-CCC414B6-5113-4CE8-AEF4-4884AFA8EC96Q34559944-81D98C76-1381-4FD1-89D4-C6DB75B77F5FQ34560763-7081E950-D5FE-4D68-ACE7-6FCB21B4E121Q34568486-19053F5A-A94A-4AB0-94A1-1A5E01A845A6Q34662589-77CACC95-D8A6-4356-973A-39BC5163ABAEQ34975192-C24FC144-2B0F-4CE7-B762-59F4A02D74CDQ35096270-CECCFCE1-1DB8-4B44-9F43-99CD6EDED7F6Q35125516-0DD99CDA-C25D-4A07-9823-C3DD0F40451BQ35442741-F531438A-20F1-4976-BA0D-0F1110E3CE73Q35612555-A948AA31-98C8-4A78-92AC-F969EA83D764Q35883857-157E4F3C-0C56-4DD8-B9AB-2F910429B103Q35927759-614BE34F-25F3-428A-B19E-0D84D66FF57EQ37173897-3CB25FB0-4E77-447B-AFEF-29A817F912ACQ37225018-717DF291-DDE2-482D-A87B-EFBFF0FAE65FQ37466735-190BCCDE-6709-4E08-92F3-8253FA6BE902Q37688760-D0075021-4C8E-4FDD-8489-9969DF0F65A9Q37724743-4B4829AF-37EA-4B29-9C36-8CBC7E77403AQ37789741-1E679437-6C81-4CFA-8152-6528855CE4BEQ37825903-3C2AB241-398E-49FA-ADA8-F1C28EB84B8EQ38075818-E79682F0-2A66-43CA-A12A-75B5B77B8A5AQ38151675-90465D6F-ED7D-4F55-958A-66440346AFDE
P2860
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@ast
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@en
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@nl
type
label
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@ast
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@en
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@nl
prefLabel
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@ast
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@en
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@nl
P2093
P2860
P3181
P356
P1476
Antagonism of Secreted PCSK9 I ...... ptor Expression in HepG2 Cells
@en
P2093
Chiyuan Chen
Hyock Joo Kwon
Jay D Horton
Justin R Chen
Markey C McNutt
Thomas A Lagace
P2860
P304
P3181
P356
10.1074/JBC.M808802200
P407
P577
2009-04-17T00:00:00Z